Welcome to Thrombosis Adviser podcast series in which renowned experts in the field of thromboembolic disease join us to discuss key medical issues, offer their views and professional analysis on recent studies, and provide you with practical information on thrombosis management.

Despite current optimised medical treatment, patients with CAD or PAD remain at high risk of cardiovascular events. With the European approval of rivaroxaban vascular dose, 2.5 mg twice daily, plus aspirin, and new European guidelines’ recommendations on vascular protection, we are in exciting times.

Join James Rudd in this episode of the Thrombosis Adviser Podcast series discussing together with Keith Fox - Professor of Cardiology at the University of Edinburgh - how to interpret the ESC 2019 Guidelines on Chronic Coronary Syndrome.

Approval No. PP-XAR-ALL-1571-1